Diagnostics was Labcorp Holdings’s largest segment in fiscal 2025, bringing in $10.88B of $14.00B (78%).
| Segment | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2016 | FY 2017 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnostics | — | $9.42B | $10.14B | $10.88B | ||||||||||
| Labcorp Diagnostics | $9.20B | — | — | — | ||||||||||
| Covance Drug Development | — | — | — | — | ||||||||||
| Routine Testing | — | — | — | — | ||||||||||
| Biopharma Laboratory Services | $2.70B | $2.77B | $2.92B | $3.10B | ||||||||||
| Genomic & Esoteric Testing | — | — | — | — | ||||||||||
| Other Segments | — | — | — | — | ||||||||||
| Ontario, Canada | — | — | — | — | ||||||||||
| Intersegment Eliminations | $36.90M | $27.70M | $58.00M | $23.00M | ||||||||||
| Total | $11.94B | $12.22B | $13.12B | $14.00B |
Labcorp Holdings brought in $14.00B from its three segments in fiscal 2025, the year ended December 31, 2025. That was up 6.6% from $13.12B in fiscal 2024. Diagnostics was the largest at $10.88B (77.7%), ahead of Biopharma Laboratory Services at $3.10B (22.1%) and Intersegment Eliminations at $23.00M (0.2%).
Compared with fiscal 2024, Diagnostics grew 7.2% to $10.88B and Biopharma Laboratory Services grew 6.0% to $3.10B.
Labcorp Holdings began breaking out Diagnostics in fiscal 2023, when it brought in $9.42B. Labcorp Holdings stopped reporting Labcorp Diagnostics as a separate segment after fiscal 2022, when it brought in $9.20B.
United States was Labcorp Holdings’s largest region in fiscal 2017, bringing in $8.23B of $10.21B (81%).
| Geography | FY 2017 |
|---|---|
| United States | $8.23B |
| Other Countries | $857.70M |
| Switzerland | $484.40M |
| Canada | $327.80M |
| United Kingdom | $302.00M |
| Total | $10.21B |
Labcorp Holdings brought in $10.21B from its five regions in fiscal 2017, the year ended December 31, 2017. United States was the largest at $8.23B (80.7%), ahead of Other Countries at $857.70M (8.4%) and Switzerland at $484.40M (4.7%). The other two regions brought in $629.80M combined.
Labcorp Holdings (LH) reports its revenue by segment and by geography. In fiscal 2025, Diagnostics was its largest segment, bringing in $10.88B (77.7% of the total), followed by Biopharma Laboratory Services at $3.10B (22.1%).
Diagnostics was Labcorp Holdings' largest segment in fiscal 2025, bringing in $10.88B, or 77.7% of the $14.00B total across its three segments.
United States was Labcorp Holdings' largest region in fiscal 2017, bringing in $8.23B, or 80.7% of the $10.21B total across its five regions.
Diagnostics grew faster than Biopharma Laboratory Services in fiscal 2025, up 7.2% from $10.14B to $10.88B. Biopharma Laboratory Services grew 6.0% to $3.10B.
Every figure comes from Labcorp Holdings' annual financial filings, as reported. Each line keeps the name Labcorp Holdings gives it, and years follow its fiscal calendar.
Labcorp Holdings' revenue by segment goes back to fiscal 2010, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.